HIV treatment and prevention 2019: current standards of care
N Phanuphak, RM Gulick - Current Opinion in HIV and AIDS, 2020 - journals.lww.com
HIV treatment and prevention 2019: current standards of care : Current Opinion in HIV and
AIDS HIV treatment and prevention 2019: current standards of care : Current Opinion in HIV …
AIDS HIV treatment and prevention 2019: current standards of care : Current Opinion in HIV …
Two‐drug vs. three‐drug combinations for HIV‐1: Do we have enough data to make the switch?
Three‐drug combination antiretroviral therapy (ART) became available in 1996, dramatically
improving the prognosis of people living with HIV. The clinical benefits of ART are due to the …
improving the prognosis of people living with HIV. The clinical benefits of ART are due to the …
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society–USA Panel
MS Saag, CA Benson, RT Gandhi, JF Hoy… - Jama, 2018 - jamanetwork.com
Importance Antiretroviral therapy (ART) is the cornerstone of prevention and management of
HIV infection. Objective To evaluate new data and treatments and incorporate this …
HIV infection. Objective To evaluate new data and treatments and incorporate this …
Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 …
Background Primary analyses of the SWORD-1 and SWORD-2 trials at 48 weeks showed
that switching to a two-drug regimen of dolutegravir plus rilpivirine was non-inferior to …
that switching to a two-drug regimen of dolutegravir plus rilpivirine was non-inferior to …
Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial
BO Taiwo, VC Marconi, B Berzins… - Clinical Infectious …, 2018 - academic.oup.com
In this randomized pilot clinical trial, dolutegravir plus lamivudine was noninferior to
continuation of standard 3-drug maintenance antiretroviral therapy. There was no …
continuation of standard 3-drug maintenance antiretroviral therapy. There was no …
A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non …
R Landman, P de Truchis, L Assoumou, S Lambert… - The Lancet …, 2022 - thelancet.com
Background Intermittent (on 4 days per week) antiretroviral therapy (ART) for patients with
HIV-1 might be more convenient, better tolerated, and cheaper than continuous treatment …
HIV-1 might be more convenient, better tolerated, and cheaper than continuous treatment …
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA) …
NI Paton, J Musaazi, C Kityo, S Walimbwa, A Hoppe… - The Lancet …, 2022 - thelancet.com
Background WHO guidelines recommend dolutegravir plus two nucleoside reverse
transcriptase inhibitors (NRTIs) for second-line HIV therapy, with NRTI switching from first …
transcriptase inhibitors (NRTIs) for second-line HIV therapy, with NRTI switching from first …
Two-drug regimens for HIV treatment
KM Gibas, SG Kelly, JR Arribas, P Cahn, C Orkin… - The Lancet …, 2022 - thelancet.com
Combination therapy with three antiretroviral agents has been integral to successful HIV-1
treatment since 1996. Although the efficacy, adverse effects, and toxicities of contemporary …
treatment since 1996. Although the efficacy, adverse effects, and toxicities of contemporary …
DOLAMA study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients
C Hidalgo-Tenorio, LL Cortés, A Gutiérrez, J Santos… - Medicine, 2019 - journals.lww.com
Dolutegravir (DTG) has shown effectiveness in combination with rilpivirine in with
experience of antiretroviral therapy (ART) and with 3TC in naïve patients (GEMINI trial). The …
experience of antiretroviral therapy (ART) and with 3TC in naïve patients (GEMINI trial). The …
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals …
R Gagliardini, A Ciccullo, A Borghetti… - Open forum …, 2018 - academic.oup.com
Background Dual therapy (DT) with boosted protease inhibitors (bPIs) plus lamivudine has
been shown to be superior to bPI monotherapy in virologically suppressed patients despite …
been shown to be superior to bPI monotherapy in virologically suppressed patients despite …